Heart Failure: Ohio state cardiologists make history | Empagliflozin for HFpEF | The benefits of stem cell therapy

The procedure, performed as part of a clinical trial, appears to have been a complete success. 

Researchers took a fresh look at data from the EMPEROR-Preserved trial, sharing their findings in Circulation.

Doctors may not want to prescribe aspirin to patients presenting with obesity, high blood pressure, diabetes or a number of other risk factors.

The authors also noted that cardiac complications such as myocarditis, MI and new-onset heart failure were rare during hospitalization for COVID-19.

“Cell therapy has the potential to change how we treat heart failure,” one researcher said.

"Every clinical outcome that we measured favored treatment with valsartan alone," one researcher said. 

The study, published in the Journal of the American Heart Association, examined how certain symptoms related to depression might be associated with a person's risk of HFpEF and HFrEF.

The investment is expected to go toward ramping up development, bringing in additional employees and more.